Hebei Medical University Fourth Hospital

Researchers are testing whether giving sacituzumab tirumotecan plus toripalimab before surgery helps people with locally advanced esophageal squamous cell carcinoma. Participants receive three cycles of the combination, then undergo standard surgery to remove the tumor. The main …

This trial tests whether giving a combination of immunotherapy (sintilimab) and two chemotherapy drugs (paclitaxel polymeric micelles and cisplatin) before surgery can help people with a certain type of esophageal cancer. The treatment aims to shrink tumors and improve the chance…

This trial tests whether adding an experimental immunotherapy drug (QL1706) to standard hormone therapy can shrink tumors in people with a common type of breast cancer (HR-positive, HER2-negative) that did not respond well to initial chemotherapy. About 40 participants whose tumo…

This trial tests a new drug called becotatug vedotin, given together with standard chemotherapy (cisplatin) and radiation, for people with a type of advanced esophageal cancer. The main goals are to find the safest dose and see how well the combination works. About 12 participant…

This study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every th…

This phase 2 trial is testing whether adding an experimental immunotherapy drug (SHR-1701) to standard chemotherapy can improve outcomes for people with a specific type of esophageal cancer (Siewert type II) that can be surgically removed. About 38 participants will receive the d…

This study tests whether a new form of chemotherapy (liposomal irinotecan) combined with other drugs works better than standard irinotecan for people with metastatic colorectal cancer that has progressed after first-line treatment. About 408 adults aged 18 to 75 will be randomly …

This study tests a personalized approach for people with HER2-positive breast cancer. After two cycles of standard therapy, those whose tumors shrink less than 40% will switch to a new drug combination (SHR-A1811 plus pertuzumab) for four more cycles before surgery. The goal is t…

This study tests a new drug called befotertinib combined with radiation therapy for people with advanced non-small cell lung cancer that has an EGFR mutation and has spread to only a few spots. The goal is to see if this combination can delay cancer growth. About 84 participants …

This phase 2 trial tests the drug olaparib in 30 women with recurrent or metastatic triple-negative breast cancer that has a specific DNA change (BRCA1 promoter methylation) but no BRCA gene mutation. Participants take olaparib pills until the disease worsens or side effects beco…

This study looks back at medical records of 2000 women with HER2-positive early breast cancer who still had cancer after initial treatment. Researchers want to see which follow-up drug regimen—trastuzumab plus pertuzumab or T-DM1—leads to better long-term outcomes. The goal is to…